共 50 条
Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft
被引:0
|作者:
Stavart, Louis
[1
,2
]
Halfon, Matthieu
[1
,2
]
Dewarrat, Natacha
[3
]
Rotman, Samuel
[4
]
Golshayan, Dela
[1
,2
,5
]
机构:
[1] Lausanne Univ Hosp CHUV, Transplantat Ctr, Lausanne, Switzerland
[2] Lausanne Univ Hosp CHUV, Transplantat Immunopathol Lab, Lausanne, Switzerland
[3] Lausanne Univ Hosp CHUV, Serv & Cent Lab Hematol, Lausanne, Switzerland
[4] Lausanne Univ Hosp CHUV, Inst Pathol, Lausanne, Switzerland
[5] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland
关键词:
chronic lymphocytic leukemia;
kidney transplantation;
Bruton tyrosine kinase inhibitor;
acute cellular rejection;
case report;
B-CELL LYMPHOCYTOSIS;
TRANSPLANTATION;
IBRUTINIB;
LYMPHOMA;
PATIENT;
DONOR;
D O I:
10.3389/fmed.2024.1451264
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after transplantation is still unclear and only based on few case series and reports. Therefore, we aimed to contribute to this understanding by reporting the first documented case of a clinically significant CLL with biopsy-proven infiltration of the kidney allograft and its successful management with a Bruton tyrosine kinase inhibitor (BTKi). We then reviewed the related literature, with a focus on CLL and kidney transplantation. Our main message is that BTKi may represent a safe and effective intervention to prevent the hazardous patient and graft outcomes of CLL in SOT patients.
引用
收藏
页数:7
相关论文